Clarivate Q3 2026 net loss more than doubles to $80.8 million

• Clarivate’s third-quarter 2026 net loss more than doubled to $80.8 million, driven by a $62.2 million noncash LS&H goodwill impairment charge.
• Revenues, including discontinued operations, fell 9% to $567.9 million from a year earlier, primarily due to inorganic disposals.
• The Life Sciences & Healthcare segment sale closed October 6, 2026, generating net cash proceeds of $488.4 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86925) on November 03, 2026, and is solely responsible for the information contained therein.